• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Tumour biology : >Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response
【24h】

Association of well-characterized lung cancer lncRNA polymorphisms with lung cancer susceptibility and platinum-based chemotherapy response

机译：特征明确的肺癌lncRNA多态性与肺癌易感性和铂类化学疗法反应的关系

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Long non-coding RNAs (lncRNAs) play important roles in carcinogenesis and drug efficacy. Platinum-based chemotherapy is first-line treatment for lung cancer chemotherapy. In this study, we aimed to investigate the association of well-characterized lung cancer lncRNA genetic polymorphisms with the lung cancer susceptibility and platinum-based chemotherapy response. A total of 498 lung cancer patients and 213 healthy controls were recruited in the study. Among them, 467 patients received at least two cycles of platinum-based chemotherapy. Thirteen polymorphisms in HOXA distal transcript antisense RNA (HOTTIP), HOX transcript antisense intergenic RNA (HOTAIR), H19, CDKN2B antisense RNA 1 (ANRIL), colon cancer-associated transcript 2 (CCAT2), metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), and maternally expressed gene 3 (MEG3) genes were genotyped by allele-specific MALDI-TOF mass spectrometry. We found that patients with HOTTIP rs5883064 C allele or rs1859168 A allele had increased lung cancer risk (P = 0.01, P = 0.01, respectively). CCAT2 rs6983267 (P = 0.02, adenocarcinoma) and H19 rs2107425 (P = 0.02, age under 50 years) showed strong relationship with lung cancer susceptibility. CCAT2 rs6983267, H19 rs2839698, MALAT1 rs619586, and HOTAIR rs7958904 were associated with platinum-based chemotherapy response in dominant model ((P = 0.02, P = 0.04, P = 0.04, P = 0.01, respectively). ANRIL rs10120688 (P = 0.02, adenocarcinoma) and rs1333049 (P = 0.04, small-cell lung cancer), H19 rs2107425 (P = 0.02, small-cell lung cancer) and HOTAIR rs1899663 (P = 0.03, male; P = 0.03, smoker) were associated with response to platinum-based chemotherapy. HOTTIP, CCAT2, H19, HOTAIR, MALATI, ANRIL genetic polymorphisms were significantly associated with lung cancer susceptibility or platinum-based chemotherapy response. They may be potential clinical biomarkers to predict lung cancer risk and platinum-based chemotherapy response.
机译：长的非编码RNA（lncRNA）在致癌作用和药物功效中起重要作用。基于铂的化学疗法是肺癌化学疗法的一线治疗。在这项研究中，我们旨在研究特征明确的肺癌lncRNA基因多态性与肺癌易感性和铂类化学疗法反应之间的关系。该研究共招募了498位肺癌患者和213位健康对照。其中，有467名患者接受了至少两个周期的铂类化疗。 HOXA远端转录反义RNA（HOTTIP），HOX转录反义基因间RNA（HOTAIR），H19，CDKN2B反义RNA 1（ANRIL），结肠癌相关转录本2（CCAT2），转移相关肺腺癌转录本1（AT13）有13个多态性），并通过等位基因特异性MALDI-TOF质谱对母本表达的基因3（MEG3）基因进行基因分型。我们发现患有HOTTIP rs5883064 C等位基因或rs1859168 A等位基因的患者罹患肺癌的风险增加（分别为P = 0.01，P = 0.01）。 CCAT2 rs6983267（P = 0.02，腺癌）和H19 rs2107425（P = 0.02，年龄在50岁以下）与肺癌易感性密切相关。 CCAT2 rs6983267，H19 rs2839698，MALAT1 rs619586和HOTAIR rs7958904在显性模型中分别与铂类化疗反应相关（（分别为P = 0.02，P = 0.04，P = 0.04，P = 0.01）.ANRIL rs10120688（P = 0.02） ，腺癌）和rs1333049（P = 0.04，小细胞肺癌），H19 rs2107425（P = 0.02，小细胞肺癌）和HOTAIR rs1899663（P = 0.03，男性; P = 0.03，吸烟者）与反应相关HOTTIP，CCAT2，H19，HOTAIR，MALATI，ANRIL基因多态性与肺癌易感性或铂类化学疗法反应显着相关，它们可能是预测肺癌风险和铂类化学疗法反应的潜在临床生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号